DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases.
The last earnings update was 78 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
DiaMedica Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
DiaMedica Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
DiaMedica Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if DiaMedica Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
DiaMedica Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
DiaMedica Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
DiaMedica Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
DiaMedica Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
DiaMedica Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
DiaMedica Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Rick Pauls, MBA has been Chief Executive Officer and President of Diamedica Inc. since July 31, 2009. Mr. Pauls was an Executive of GMAC Residential Funding of Canada Ltd. He served as the President of Sanomune Inc. He served as Managing Director of CentreStone Ventures Inc., the General Partner of CentreStone Ventures LP since February 2002. He was involved in all aspects of the management of CentreStone. He served as Chief Executive Officer and President of Diamedica Inc. from 2009 to 2010. He served as Acting Chief Executive Officer of Diamedica Inc. since July 31, 2009 until June 29, 2010. He served as the Chief Executive Officer and President of Diamedica Inc. until February 9, 2009. He served as Interim President and Interim Chief Executive Officer of Diamedica Inc. since April 8, 2008 and its Secretary since April 2005. He served as the Director of Venture Finance at Genesys Venture Inc. He served as an Analyst from August 1999 to February 2001 at Centara Corporation. Mr. Pauls has also worked in business development roles for both private and public life sciences and information technology companies. He was with General Motors Acceptance Corporation in Minneapolis, Minnesota, where he specialized in asset-backed securitization and structured finance. He served as the Chairman of Diamedica Inc. from April 8, 2008 to July 7, 2014 and has been its Director since April 2005. He serves as a Director of TechStars, LLC., Verista Imaging, Inc. and LED Dental, Inc. He served as an Independent Director of LED Medical Diagnostics, Inc. since October 15, 2008 until August 22, 2017. He served as a Director of Orasi Medical, Inc. Mr. Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.
Rick's compensation has increased whilst company is loss making.
Rick's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the DiaMedica Therapeutics management team is about average.
CEO, President & Director
Chief Scientific Officer
CFO & Company Secretary
Chief Commercial Advisor
Consulting Chief Medical Officer
Chief Medical Officer
Vice President of Business Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the DiaMedica Therapeutics board of directors is about average.
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company’s lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.